Overview

* Boston Scientific ( BSX ) Q3 revenue grows 20.3%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reaching $0.75

* Company discontinues sales of ACURATE valve systems globally

Outlook

* Boston Scientific ( BSX ) estimates full-year 2025 net sales growth of ~20% reported, 15.5% organic

* Company expects Q4 2025 net sales growth of 14.5%-16.5% reported, 11%-13% organic

* Boston Scientific ( BSX ) projects full-year 2025 GAAP EPS of $1.97-$2.01, adjusted EPS $3.02-$3.04

Result Drivers

* CARDIOVASCULAR GROWTH - Cardiovascular segment reported a 22.4% increase in sales, driven by strong demand

* U.S. MARKET STRENGTH - U.S. sales grew 27% on both reported and operational basis, leading regional performance

* INNOVATION FOCUS - CEO attributes strong performance to category leadership strategy and innovation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $5.06 $4.96

Revenue bln bln (26

Analysts

)

Q3 Beat $0.75 $0.71

ADJUSTED (25

EPS Analysts

)

Q3 EPS $0.51

Q3 Net $755 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 35 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Boston Scientific Corp ( BSX ) is $125.00, about 20.1% above its October 21 closing price of $99.90

* The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 35 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)